Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Daniel Bowles

Concepts (346)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
31
2026
2202
3.360
 Why?
Head and Neck Neoplasms
16
2023
562
2.850
 Why?
Salivary Gland Neoplasms
8
2023
39
2.820
 Why?
Protein Kinase Inhibitors
15
2026
974
2.230
 Why?
Carcinoma, Squamous Cell
14
2019
643
2.210
 Why?
Pyridines
14
2026
605
2.120
 Why?
Thyroid Neoplasms
9
2024
349
1.830
 Why?
Carcinoma, Non-Small-Cell Lung
9
2026
1183
1.710
 Why?
Molecular Targeted Therapy
7
2021
434
1.630
 Why?
Neoplasm Recurrence, Local
7
2023
1148
1.540
 Why?
Protein-Tyrosine Kinases
4
2021
433
1.430
 Why?
Antineoplastic Combined Chemotherapy Protocols
14
2024
1962
1.420
 Why?
Neoplasms
20
2024
2887
1.400
 Why?
Lung Neoplasms
11
2026
2652
1.380
 Why?
Anilides
6
2024
84
1.330
 Why?
Gonanes
7
2016
28
1.320
 Why?
Proto-Oncogene Proteins
6
2021
624
1.300
 Why?
Thyroid Carcinoma, Anaplastic
3
2020
36
1.240
 Why?
Cetuximab
7
2018
111
1.230
 Why?
Biomarkers, Tumor
8
2020
1325
1.200
 Why?
Adenocarcinoma
7
2024
931
1.180
 Why?
Phosphatidylinositol 3-Kinases
8
2017
381
0.800
 Why?
Pyrazoles
6
2026
510
0.790
 Why?
Mutation
13
2024
4104
0.740
 Why?
Carcinoma
3
2019
228
0.710
 Why?
Phytotherapy
2
2012
74
0.680
 Why?
Drugs, Investigational
2
2011
31
0.680
 Why?
Neoplasm Staging
15
2019
1470
0.660
 Why?
Cisplatin
6
2024
336
0.660
 Why?
Neoplasms, Second Primary
1
2021
100
0.620
 Why?
Papillomaviridae
4
2019
115
0.610
 Why?
Disease-Free Survival
10
2017
771
0.610
 Why?
Taxoids
3
2015
116
0.600
 Why?
Antineoplastic Agents, Immunological
2
2018
201
0.590
 Why?
Quinolines
5
2024
193
0.590
 Why?
Hedgehog Proteins
3
2015
197
0.590
 Why?
Carcinoma, Renal Cell
3
2017
234
0.580
 Why?
Pyrimidines
6
2026
533
0.570
 Why?
Humans
90
2026
145305
0.570
 Why?
Marijuana Smoking
2
2012
250
0.550
 Why?
Tumor Suppressor Proteins
2
2018
324
0.540
 Why?
Proto-Oncogene Proteins c-ret
5
2026
41
0.540
 Why?
Drug Resistance, Neoplasm
8
2024
886
0.540
 Why?
Middle Aged
44
2026
36021
0.510
 Why?
Kidney Neoplasms
3
2017
413
0.510
 Why?
Carcinoma, Mucoepidermoid
1
2017
17
0.510
 Why?
Colorectal Neoplasms
2
2016
849
0.500
 Why?
Aged
40
2026
26001
0.500
 Why?
Carcinoma, Transitional Cell
4
2017
69
0.490
 Why?
Ubiquitin Thiolesterase
1
2017
68
0.490
 Why?
Carcinoma, Ductal
1
2016
10
0.490
 Why?
Adenoma, Pleomorphic
1
2016
9
0.490
 Why?
Sulfones
2
2014
127
0.480
 Why?
Gene Rearrangement
2
2018
155
0.480
 Why?
Cannabinoids
2
2024
182
0.470
 Why?
Glycine
2
2014
187
0.470
 Why?
Maximum Tolerated Dose
5
2017
212
0.440
 Why?
Melanoma
1
2021
761
0.420
 Why?
Drug Interactions
6
2017
401
0.410
 Why?
Enzyme Inhibitors
3
2014
826
0.410
 Why?
Pyrroles
1
2014
218
0.390
 Why?
Iodine Radioisotopes
5
2024
137
0.390
 Why?
Gene Fusion
3
2023
29
0.390
 Why?
Signal Transduction
8
2018
5239
0.390
 Why?
Phenylurea Compounds
4
2024
112
0.380
 Why?
Receptor Protein-Tyrosine Kinases
2
2012
230
0.380
 Why?
Male
45
2026
72628
0.380
 Why?
Genetic Variation
1
2018
986
0.380
 Why?
Lymph Nodes
4
2017
502
0.370
 Why?
Aged, 80 and over
16
2026
8295
0.370
 Why?
Indazoles
3
2019
83
0.360
 Why?
Female
46
2026
78605
0.360
 Why?
Quinazolines
1
2013
266
0.350
 Why?
Class I Phosphatidylinositol 3-Kinases
4
2017
109
0.350
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2012
127
0.340
 Why?
Treatment Outcome
15
2024
11731
0.340
 Why?
Antibodies, Monoclonal, Humanized
4
2024
991
0.330
 Why?
Neoplasm Metastasis
6
2021
697
0.320
 Why?
Adult
27
2026
40627
0.300
 Why?
Prognosis
9
2021
4310
0.280
 Why?
ErbB Receptors
4
2017
630
0.280
 Why?
Benzamides
3
2022
227
0.270
 Why?
Pharmacogenomic Variants
2
2018
33
0.260
 Why?
Papillomavirus Infections
3
2022
346
0.260
 Why?
Urologic Neoplasms
2
2017
31
0.250
 Why?
Nitriles
2
2022
205
0.250
 Why?
Carcinoma, Ductal, Breast
1
2007
88
0.250
 Why?
Mitoxantrone
1
2006
15
0.250
 Why?
Platinum
2
2024
52
0.250
 Why?
Xenograft Model Antitumor Assays
7
2024
931
0.240
 Why?
Enterobacter
1
2006
9
0.240
 Why?
Tooth Diseases
1
2006
13
0.240
 Why?
Esophageal and Gastric Varices
1
2006
36
0.230
 Why?
Enterobacteriaceae Infections
1
2006
41
0.230
 Why?
Gene Expression Profiling
5
2018
1787
0.230
 Why?
Salivary Glands
2
2023
36
0.230
 Why?
Oropharyngeal Neoplasms
2
2016
55
0.230
 Why?
Acute Kidney Injury
3
2018
870
0.220
 Why?
Animals
16
2024
38177
0.220
 Why?
Serotonin 5-HT3 Receptor Antagonists
1
2024
5
0.220
 Why?
Chemoradiotherapy
4
2020
239
0.220
 Why?
Proto-Oncogene Proteins B-raf
2
2024
226
0.220
 Why?
Clinical Trials as Topic
3
2018
1063
0.210
 Why?
Cannabis
1
2011
509
0.210
 Why?
Receptors, Estrogen
1
2007
458
0.210
 Why?
Antiemetics
1
2024
49
0.210
 Why?
Immunotherapy
2
2023
660
0.210
 Why?
Urinary Bladder Neoplasms
2
2017
260
0.200
 Why?
Registries
2
2016
2398
0.200
 Why?
Liver Cirrhosis
1
2006
288
0.200
 Why?
Carcinoma, Adenoid Cystic
1
2023
19
0.200
 Why?
Combined Modality Therapy
4
2018
1268
0.200
 Why?
Bacteremia
1
2006
223
0.200
 Why?
Gene Expression Regulation, Neoplastic
3
2019
1462
0.200
 Why?
Models, Biological
3
2024
1823
0.200
 Why?
Administration, Oral
3
2014
848
0.190
 Why?
Phenylthiohydantoin
1
2022
44
0.180
 Why?
Medical Marijuana
1
2024
123
0.180
 Why?
Survival Rate
5
2021
2100
0.170
 Why?
Radiation Pneumonitis
1
2021
31
0.170
 Why?
Drug Evaluation, Preclinical
2
2013
194
0.170
 Why?
Chemotherapy, Adjuvant
3
2017
425
0.170
 Why?
Survival Analysis
4
2020
1386
0.170
 Why?
Referral and Consultation
1
2007
853
0.170
 Why?
Carcinoma, Neuroendocrine
1
2021
36
0.170
 Why?
Disease Susceptibility
2
2020
348
0.160
 Why?
Adrenal Cortex Neoplasms
1
2021
65
0.160
 Why?
Adrenocortical Carcinoma
1
2021
67
0.160
 Why?
TOR Serine-Threonine Kinases
2
2016
451
0.160
 Why?
Gene Expression
2
2015
1490
0.160
 Why?
Cystectomy
2
2017
42
0.160
 Why?
SEER Program
1
2021
225
0.160
 Why?
Receptors, Nerve Growth Factor
1
2019
18
0.150
 Why?
Kaplan-Meier Estimate
3
2017
967
0.150
 Why?
DNA Mutational Analysis
2
2018
409
0.150
 Why?
Leukemia, Myeloid, Acute
1
2006
684
0.150
 Why?
Lymph Node Excision
2
2017
174
0.150
 Why?
Tracheal Neoplasms
1
2019
12
0.150
 Why?
Prostatic Neoplasms
1
2006
979
0.140
 Why?
Smad4 Protein
1
2019
34
0.140
 Why?
United States
8
2021
16051
0.140
 Why?
Positron Emission Tomography Computed Tomography
1
2020
117
0.140
 Why?
Alphapapillomavirus
2
2016
35
0.140
 Why?
Radiosurgery
1
2022
401
0.140
 Why?
Benzazepines
1
2018
35
0.140
 Why?
Genetic Heterogeneity
1
2019
65
0.140
 Why?
Risk
1
2021
912
0.140
 Why?
Disease Management
2
2020
647
0.140
 Why?
Genomics
3
2021
842
0.140
 Why?
Chromosome Aberrations
1
2019
163
0.140
 Why?
DNA Mismatch Repair
1
2018
53
0.130
 Why?
Tissue Fixation
1
2017
37
0.130
 Why?
Paraffin Embedding
1
2017
33
0.130
 Why?
Smokers
1
2018
137
0.130
 Why?
Oncogenes
1
2018
119
0.130
 Why?
Erlotinib Hydrochloride
1
2017
72
0.130
 Why?
Formaldehyde
1
2017
66
0.130
 Why?
Nasopharyngeal Neoplasms
1
2017
21
0.130
 Why?
Gene Deletion
1
2019
389
0.130
 Why?
Radiotherapy, Intensity-Modulated
1
2018
142
0.130
 Why?
DNA, Neoplasm
1
2017
164
0.130
 Why?
Neoplasm Grading
1
2018
310
0.130
 Why?
Health Services Needs and Demand
1
2019
281
0.130
 Why?
Gene Frequency
1
2018
481
0.120
 Why?
Chemoradiotherapy, Adjuvant
1
2016
44
0.120
 Why?
Induction Chemotherapy
1
2017
87
0.120
 Why?
Salivary Ducts
1
2016
2
0.120
 Why?
Palliative Care
2
2018
1012
0.120
 Why?
Laryngeal Neoplasms
1
2016
36
0.120
 Why?
Muscle, Smooth
1
2017
153
0.120
 Why?
Carboplatin
1
2016
161
0.120
 Why?
Nomograms
1
2016
59
0.120
 Why?
Dose-Response Relationship, Drug
3
2017
2032
0.120
 Why?
Patient Navigation
1
2018
111
0.120
 Why?
Database Management Systems
1
2016
50
0.120
 Why?
Hospice and Palliative Care Nursing
1
2018
113
0.120
 Why?
Prospective Studies
7
2024
8011
0.120
 Why?
Disease Progression
4
2018
2855
0.110
 Why?
Population Surveillance
1
2019
485
0.110
 Why?
Young Adult
5
2021
14163
0.110
 Why?
Computational Biology
2
2018
683
0.110
 Why?
Angiopoietin-1
1
2015
12
0.110
 Why?
Angiopoietin-2
1
2015
15
0.110
 Why?
Radiotherapy
1
2016
206
0.110
 Why?
Incidence
2
2019
2892
0.110
 Why?
Bone Neoplasms
1
2017
256
0.110
 Why?
Zinc Finger Protein GLI1
1
2014
26
0.110
 Why?
Genetic Testing
1
2018
482
0.110
 Why?
Retrospective Studies
8
2021
17149
0.110
 Why?
Retreatment
1
2014
77
0.110
 Why?
Hospice Care
1
2018
220
0.110
 Why?
Response Evaluation Criteria in Solid Tumors
1
2014
21
0.110
 Why?
Breast Neoplasms
1
2007
2464
0.110
 Why?
Piperazines
2
2018
381
0.100
 Why?
Neoplasms, Unknown Primary
1
2014
20
0.100
 Why?
Proto-Oncogene Proteins c-akt
1
2016
437
0.100
 Why?
Neoplastic Stem Cells
1
2018
412
0.100
 Why?
Paclitaxel
1
2015
256
0.100
 Why?
High-Throughput Nucleotide Sequencing
1
2017
550
0.100
 Why?
Patient Satisfaction
1
2018
706
0.100
 Why?
Veratrum Alkaloids
1
2013
20
0.100
 Why?
Sulfonamides
1
2017
581
0.100
 Why?
ras Proteins
1
2014
151
0.100
 Why?
Promoter Regions, Genetic
1
2018
1260
0.100
 Why?
Proportional Hazards Models
4
2017
1328
0.100
 Why?
Proto-Oncogene Proteins p21(ras)
1
2014
253
0.100
 Why?
PTEN Phosphohydrolase
1
2014
165
0.100
 Why?
Cell Cycle Proteins
2
2014
630
0.090
 Why?
Pilot Projects
2
2015
1894
0.090
 Why?
Imatinib Mesylate
1
2012
77
0.090
 Why?
Dasatinib
1
2012
57
0.090
 Why?
Recombinant Fusion Proteins
1
2015
675
0.090
 Why?
Risk Assessment
2
2019
3686
0.090
 Why?
Thiazoles
1
2012
136
0.090
 Why?
Smoking
1
2019
1472
0.090
 Why?
Aniline Compounds
1
2012
119
0.090
 Why?
Hematopoietic Stem Cells
1
2015
420
0.090
 Why?
Biomarkers
3
2018
4284
0.090
 Why?
Proto-Oncogene Proteins c-met
1
2012
76
0.090
 Why?
Biological Availability
1
2011
142
0.090
 Why?
Evidence-Based Medicine
2
2012
737
0.080
 Why?
Phosphatidylinositol 3-Kinase
1
2011
25
0.080
 Why?
Imidazoles
1
2012
254
0.080
 Why?
Mice
7
2024
18394
0.080
 Why?
Vascular Endothelial Growth Factor A
2
2024
557
0.080
 Why?
Adolescent
5
2022
22507
0.080
 Why?
Propensity Score
3
2017
370
0.080
 Why?
Tumor Microenvironment
1
2015
736
0.080
 Why?
Cell Line, Tumor
4
2024
3560
0.080
 Why?
Phenotype
1
2018
3172
0.080
 Why?
Algorithms
1
2018
1846
0.080
 Why?
Genetic Predisposition to Disease
1
2018
2371
0.080
 Why?
Kidney
1
2017
1499
0.070
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2024
109
0.070
 Why?
Multivariate Analysis
3
2017
1540
0.070
 Why?
Adaptation, Psychological
1
2014
717
0.070
 Why?
Brain Neoplasms
1
2018
1327
0.070
 Why?
Axilla
1
2007
51
0.070
 Why?
Clinical Trials, Phase I as Topic
2
2019
52
0.060
 Why?
Cohort Studies
4
2022
5982
0.060
 Why?
Neoadjuvant Therapy
2
2022
463
0.060
 Why?
Sentinel Lymph Node Biopsy
1
2007
118
0.060
 Why?
RNA, Messenger
1
2014
2833
0.060
 Why?
Transcription Factors
1
2014
1746
0.060
 Why?
Mastectomy
1
2007
162
0.060
 Why?
Ligation
1
2006
92
0.060
 Why?
Pain
1
2011
784
0.060
 Why?
Stress, Psychological
1
2014
1153
0.060
 Why?
Creatinine
2
2018
510
0.060
 Why?
Fatal Outcome
1
2006
307
0.060
 Why?
Caregivers
1
2014
1056
0.060
 Why?
Lymphatic Metastasis
2
2017
335
0.060
 Why?
Neoplasm Invasiveness
2
2017
510
0.060
 Why?
Receptors, Progesterone
1
2007
357
0.060
 Why?
Granisetron
1
2024
6
0.060
 Why?
Quinuclidines
1
2024
11
0.060
 Why?
Ondansetron
1
2024
19
0.060
 Why?
Double-Blind Method
2
2021
2033
0.050
 Why?
Skin Neoplasms
1
2012
847
0.050
 Why?
Gastrointestinal Hemorrhage
1
2006
137
0.050
 Why?
Isoquinolines
1
2024
44
0.050
 Why?
Risk Factors
1
2019
10816
0.050
 Why?
Neoplasm Proteins
1
2007
444
0.050
 Why?
Oncogene Proteins, Fusion
1
2026
211
0.050
 Why?
Glomerular Filtration Rate
2
2018
764
0.050
 Why?
Demography
2
2015
288
0.050
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2023
86
0.050
 Why?
Benzimidazoles
1
2024
190
0.050
 Why?
Recurrence
2
2018
1138
0.050
 Why?
Databases, Factual
2
2019
1488
0.040
 Why?
Four-Dimensional Computed Tomography
1
2021
38
0.040
 Why?
Androgen Antagonists
1
2022
92
0.040
 Why?
Immunohistochemistry
2
2018
1718
0.040
 Why?
Pulmonary Ventilation
1
2021
83
0.040
 Why?
Receptors, Androgen
1
2022
153
0.040
 Why?
Radiotherapy Planning, Computer-Assisted
1
2021
149
0.040
 Why?
Quality of Life
1
2013
3197
0.040
 Why?
Receptor, trkC
1
2019
10
0.040
 Why?
Receptor, trkA
1
2019
18
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
77
0.040
 Why?
Receptor, trkB
1
2019
39
0.040
 Why?
Trastuzumab
1
2019
118
0.040
 Why?
Extracellular Signal-Regulated MAP Kinases
1
2020
173
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
39
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2019
323
0.030
 Why?
Phthalazines
1
2018
64
0.030
 Why?
Organic Cation Transporter 2
1
2017
8
0.030
 Why?
Glutathione S-Transferase pi
1
2017
10
0.030
 Why?
Retroperitoneal Space
1
2017
18
0.030
 Why?
Organic Cation Transport Proteins
1
2017
25
0.030
 Why?
Urinary Diversion
1
2017
13
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
52
0.030
 Why?
Tumor Cells, Cultured
1
2019
920
0.030
 Why?
Social Work
1
2018
85
0.030
 Why?
Margins of Excision
1
2017
51
0.030
 Why?
Membrane Glycoproteins
1
2019
501
0.030
 Why?
Immunophenotyping
1
2018
322
0.030
 Why?
Hospitals, Veterans
1
2018
259
0.030
 Why?
Laryngectomy
1
2016
17
0.030
 Why?
Kidney Function Tests
1
2017
157
0.030
 Why?
Oncologists
1
2017
46
0.030
 Why?
Cation Transport Proteins
1
2017
118
0.030
 Why?
Viral Core Proteins
1
2016
22
0.030
 Why?
Pelvis
1
2017
124
0.030
 Why?
Carcinogenesis
1
2018
229
0.030
 Why?
Regression Analysis
1
2018
1003
0.030
 Why?
Heart
1
2020
636
0.030
 Why?
Radiotherapy, Adjuvant
1
2016
223
0.030
 Why?
Disease Models, Animal
2
2018
4580
0.030
 Why?
Internationality
1
2016
156
0.030
 Why?
Random Allocation
1
2016
363
0.030
 Why?
Anti-Bacterial Agents
1
2006
1922
0.030
 Why?
Antibodies, Neoplasm
1
2015
35
0.030
 Why?
Antibodies, Monoclonal
1
2022
1525
0.030
 Why?
Biopsy, Large-Core Needle
1
2014
15
0.030
 Why?
Myocardium
1
2020
940
0.030
 Why?
Robotic Surgical Procedures
1
2017
183
0.030
 Why?
Analysis of Variance
1
2017
1311
0.030
 Why?
Bone Marrow
1
2015
306
0.020
 Why?
Receptor, Notch2
1
2013
15
0.020
 Why?
Receptor Cross-Talk
1
2013
21
0.020
 Why?
Receptor, Notch1
1
2013
64
0.020
 Why?
Metabolic Clearance Rate
1
2012
115
0.020
 Why?
Psychiatric Status Rating Scales
1
2014
541
0.020
 Why?
Pandemics
1
2021
1698
0.020
 Why?
Gene Silencing
1
2013
205
0.020
 Why?
Nausea
1
2012
111
0.020
 Why?
Logistic Models
1
2017
2119
0.020
 Why?
Transcriptome
1
2018
1046
0.020
 Why?
Vomiting
1
2012
131
0.020
 Why?
Area Under Curve
1
2012
332
0.020
 Why?
Needs Assessment
1
2014
406
0.020
 Why?
Mice, Nude
1
2013
688
0.020
 Why?
Diarrhea
1
2012
194
0.020
 Why?
Blotting, Western
1
2013
1187
0.020
 Why?
Drug Administration Schedule
1
2012
783
0.020
 Why?
Fatigue
1
2012
366
0.020
 Why?
Cell Proliferation
1
2017
2506
0.020
 Why?
Time Factors
1
2019
7186
0.020
 Why?
Age Factors
1
2016
3339
0.020
 Why?
Lung
1
2021
4112
0.020
 Why?
Colorado
1
2018
4579
0.020
 Why?
Cytokines
1
2015
2066
0.020
 Why?
Follow-Up Studies
1
2016
5431
0.020
 Why?
Surveys and Questionnaires
1
2018
6079
0.010
 Why?
Cross-Sectional Studies
1
2014
5883
0.010
 Why?
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (346) concept(s)
_
Co-Authors Expand Description
See all (69) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)